Pearce IP’s CEO, Naomi Pearce, speaks with our Heads of Litigation for Australia and New Zealand about the practice of “skinny labelling” of generic drugs. They discuss whether a “skinny label” approach will assist in avoiding patent infringement of method of treatment or Swiss-style claims in Australia and New Zealand respectively.
On-Demand Pearce IP Webinars
A “Skinny Label” applies to a generic or biosimilar pharmaceutical that has marketing authorisation for some but not all indications for which the innovator reference drug is approved. The excluded indications are typically ones where treatment with the drug in question would carry a risk of infringing method of treatment or Swiss-style patent claims. The effectiveness of this strategy varies by jurisdiction. This episode will be of interest to those working with either innovator patent owners or generic manufacturers with an interest in the potential for circumvention of secondary pharmaceutical patents in Australia or New Zealand.
Watch our experts chew the fat on skinny label strategies in Australia and New Zealand.
Enter your email below to access our webinars
Loading… Stream